Skip to main navigation

Utility Menu

  • Patients
  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English

Utility Menu

  • Patients
  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
  • Our Science
    • RNA Platform
    • Gene Therapy
    • Manufacturing
    • Strategic Partnerships
    • Investigator-Initiated Studies
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

Corporate Governance

  • Home
  • Investor Relations
  • Corporate Governance

IR Menu

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

Corporate Governance

Governance Documents

Code of Business Conduct and Ethics
California Comprehensive Compliance Program
U.S. Political Spending Policy
Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Committee Charter

Committee Composition

Audit Committee Compensation Committee Nominating and Corporate Governance Committee Research and Development Committee
Richard J. Barry Audit Committee Compensation Committee Nominating and Corporate Governance Committee
M. Kathleen Behrens, PhD Audit Committee
Kathryn Boor, PhD Compensation Committee Nominating and Corporate Governance Committee
Michael Chambers Research and Development Committee
Deirdre Connelly Compensation Committee Nominating and Corporate Governance Committee
Douglas S. Ingram
Stephen L. Mayo, PhD Audit Committee Research and Development Committee
Claude Nicaise, MD Compensation Committee Research and Development Committee
Hans Wigzell MD, PhD Nominating and Corporate Governance Committee Research and Development Committee
= Chairperson = Member = Financial Expert = Chairman of the Board

Toolkit

Print Page | Email Alerts | RSS Feeds | Contacts

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
  • Our Science
    • RNA Platform
    • Gene Therapy
    • Manufacturing
    • Strategic Partnerships
    • Investigator-Initiated Studies
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2026 Sarepta Therapeutics, Inc. All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • Data Privacy Framework Policy